CAS: 7783-97-3; Silver,Iodate
该化合物是无机化合物,其特点是形成银离子和碘离子,通常看起来像白色或黄色的黄色固体,在水中相对溶解.银碘在正常条件下具有稳定性,但在取暖时可以分解,释放碘.它显示出银盐的典型特性,包括抗微生物活动,这导致其用于各种用途,包括摄影和作为分析化学的试剂.该化合物可以通过银硝酸盐与碘酸盐的反应合成,导致银碘酸盐的降水.在安全方面,尽管它不被列为毒性很高,但应当采取适当的处理预防措施,因为银化合物和碘可能带来危害.
- ⚠️危险化学品目录(2015年版) 氧化性固体,类别2
- 英文名称Silver,Iodate
- 中文名称碘酸银
- IUPAC名称silver iodate
- 其它别名iodic acid, silver salt; silveriodate; Iodic acid silver salt; Silver iodate
- CAS编号7783-97-3
- MFCD编号:MFCD00014150
- EINECS号:232-039-6
- FDA UNII编号:5P7OX4VT1F
- 分子式:AgHIO3分子量:283.78
- 产品CID: 1773124
- 产品分类无机化工 → 无机盐 → 金属卤化物及卤酸盐
- 相似结构搜索
- 产品信息参考
- InChIKey: YSVXTGDPTJIEIX-UHFFFAOYSA-M
- 1S/Ag.HIO3/c;2-1(3)4/h;(H,2,3,4)/q+1;/p-1
- 计算化学: 氢键受体数3.0氢键供体数1.0可旋转键数*
物理性质
- 熔点>200 °C (分解)
- 沸点200 °C (分解)>>200 °C (分解)
- 密度5.525 g/mL at 25 °C(文献)
- PSA:57.2
- LogP:0.5293
- 溶解性Practically Insoluble In Water. Soluble In Aqueous Ammonia
- 敏感性光敏感
- 外观形态白色粉末
- 储存条件储存注意事项储存于阴凉、通风的库房。远离火种、热源。库温不超过30°C，相对湿度不超过80%。避免光照。包装密封保存。应与易（可）燃物、还原剂、活性金属粉末等分开存放，切忌混储。储区应备有合适的材料收容泄漏物。
- 产品应用分析上用于测定血中的小量氯化物.
- 性质描述白色棱开结晶或粉末,微溶于水,溶于硝酸,氨水,详见MSDS
MSDS等安全信息
- GHS象形图
- GHS符号GHS03 & GHS07;
注释: Flame over circle & Exclamation mark - 危险类别Ox. Sol. 2
皮肤腐蚀/刺激 类别2
严重眼刺激 类别2
特定目标器官毒性 - 单次接触 类别3 - 警示词Danger(危险)
- 危险描述H272 |可能加剧火灾;氧化剂.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
H335 |可能引起呼吸道刺激. - 防范说明P210a-P220-P221-P305+P351+P338-P405-P501a
- 危险等级5.1
- UN编号1479.0
- 危险品标志O,Xi
- 包装等级II
- 安全声明17-26-36/37/39
- 危险类别码8-36/37/38
- WGK Germany3
欧盟法规
ECHA物质C&L通报REACH预注册上下游产品
CAS号15606-77-6 silver,periodate | CAS号7440-22-4 纳米银粉 | CAS号7782-68-5 碘酸 | CAS号15065-65-3 hypoiodite | CAS号14701-21-4 Silver, ion | CAS号506-78-5 碘化氰 | CAS号563-63-3 乙酸银 | CAS号20667-12-3 氧化银 | CAS号696-33-3 碘酰苯 | CAS号7758-05-6 碘酸钾 | CAS号20667-12-3 氧化银 | CAS号7446-07-3 二氧化碲 | CAS号865-44-1 三氯化碘 | CAS号7782-68-5 碘酸 | CAS号7783-89-3 溴酸银 | CAS号14693-81-3 碘化钽 | CAS号15606-77-6 silver,periodate | CAS号7553-56-2 碘合成工艺路线路线简述
专利信息
专利号:WO-2014029013-A1
优先权日:2012-08-22
标题:Method for producing silver(i) orthoperiodates
发明人：NADWORNY PATRICIA L; PROSPERI-PORTA GRAEME; UNRAU KEVIN R
权利人:INNOVOTECH INC
摘要:The present invention relates to the synthesis of silver(I) orthoperiodates, preferably Ag 5 IO 6 . The synthesis process comprises mixing in an aqueous solution a hydroxide, a periodate, and a source of single valency silver ions; and allowing the silver(I) orthoperiodate to form.
专利号:US-5334588-A
优先权日:1987-02-25
标 题 :Composition for inhibiting transmission of hepatitis B virus
发明人：FOX CHARLES L JR; MODAK SHANTA M
权利人:UNIV COLUMBIA
摘要:PCT No. PCT/US89/04642 Sec. 371 Date Jun. 4, 1991 Sec. 102(e) Date Jun. 4, 1991 PCT Filed Oct. 17, 1989 PCT Pub. No. WO90/04390 PCT Pub. Date May 3, 1990.The present invention relates to methods of inhibiting transmission of Hepatitis B virus using compositions comprising silver sulfadiazine and preferably further comprising a biguanide such as chlorhexidine and/or a detergent such as sodium deoxycholate. It is based, at least in part, on the discovery that silver sulfadiazine alone or in combination with chlorhexidine or sodium deoxycholate was shown to inhibit Hepatitis B virus DNA synthesis. The inhibitory effect of silver sulfadiazine was enhanced by combining silver sulfadiazine with either chlorhexidine or sodium deoxycholate.
专利号:CN-109585053-A
优先权日:2018-11-08
标 题:One-step synthesis method of ternary composite conductive powder
专利号:CN-109485833-A
优先权日:2018-11-08
标 题:A kind of synthesis method of Cu-PEDOT composite conductive powder
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
合成参考文献
摘要:L808: ATSDR - Agency for Toxic Substances and Disease Registry (1990). Toxicological profile for silver. U.S. Public Health Service in collaboration with U.S. Environmental Protection Agency (EPA).
摘要:A245: Kim S, Choi JE, Choi J, Chung KH, Park K, Yi J, Ryu DY: Oxidative stress-dependent toxicity of silver nanoparticles in human hepatoma cells. Toxicol In Vitro. 2009 Sep;23(6):1076-84. doi: 10.1016/j.tiv.2009.06.001. Epub 2009 Jun 7.
摘要:A246: Dillard CJ, Tappel AL: Mercury, silver, and gold inhibition of selenium-accelerated cysteine oxidation. J Inorg Biochem. 1986 Sep;28(1):13-20.
📝 需求与反馈
尽可能描述清楚需求与问题信息
